Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by JOHANNESSEN, T.
Right arrow Articles by FOSSTVEDT, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JOHANNESSEN, T.
Right arrow Articles by FOSSTVEDT, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Family Practice Vol. 8, No. 4, 384-387
© Oxford University Press 1991

research-article

Statistical Power in Single Subject Trials

TERJE JOHANNESSEN and DANIEL FOSSTVEDT

Department of Community Medicine and General Practice, University of Trondheim, Medical Technical Centre N-7005 Trondheim, Norway

A controlled single subject trial compares the efficacy of a new treatment with a control treatment in an individual patient. The treatments are administered in a double-blind, randomized, multi-crossover sequence of periods. During the trial response measures are obtained from each treatment period and form the basis for the statistical evaluation. Similar to the situation in clinical trials using groups of patients the statistical power is dependent on sample size, variability of responses, magnitude of the differential treatment effect and the level of statistical significance. In addition, the randomization procedure is of importance and power estimations show that a pairwise random allocation of treatment periods is more powerful than an unrestricted randomization. Since a single subject trial is a time consuming approach, the total number of treatment periods, the sample size, is restricted in order to make such trials feasible. Accordingly, less rigorous statistical requirements and power must be accepted. The consequence is an increased risk of both Type I and II errors. However, in comparison with the trial and error approach frequently applied in clinical practice, the controlled single subject trial may improve the certainty of therapeutic decisions in the individual patient.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
M. A. Bowman, J. K. Kirk, R. Michielutte, and J. S. Preisser
Use of Amantadine for Chronic Fatigue Syndrome
Arch Intern Med, June 9, 1997; 157(11): 1264 - 1265.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.